IRB #

STUDY00019402

Title

A Phase II study of intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Principal Investigator

Alexey Danilov

Study Purpose

The purpose of the study is to see the effects, good or bad, of giving Duvelisib to study participants with relapsed or refractory CLL/SLL, and using an alternative dosing schedule reduce side effects without compromising efficacy

Medical Condition(s)

Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia

Eligibility Criteria

-Men and women 18 years of age and older
-Histologically or flow cytometry confirmed diagnosis of B-CLL/SLL
-Prior chemotherapy, immunotherapy or targeted therapy and have had either documented disease progression or no response (stable disease) to the most recent treatment regimen

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

Participants will continue on study treatment until disease progression, or upon recurrence of predefined adverse events. Duration of follow-up is until death, next therapy or a minimum of 12 months end of treatment

Minors Included

No

Contact

trials@ohsu.edu
503-494-1080

Sponsor

Recruitment End

01/01/2023

Compensation Provided

No


Go Back